Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cytokines in tumor therapy].

J R Kalden1

  • 1Institut und Poliklinik für klinische Immunologie und Rheumatologie der Universität Erlangen-Nürnberg.

Onkologie
|August 1, 1987
PubMed
Summary

Interferon alpha is effective for certain leukemias and benign conditions. New cytokine-based therapies show promise for various cancers, including lymphomas and solid tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[80 milestones in rheumatology from 80 years. II. 1961-1980].

Zeitschrift fur Rheumatologie·2021
Same author

Preface.

Seminars in arthritis and rheumatism·2019
Same author

Advances in targeted therapies 2017.

Clinical immunology (Orlando, Fla.)·2018
Same author

[Erratum to: Biologics].

Zeitschrift fur Rheumatologie·2016
Same author

[Biologics].

Zeitschrift fur Rheumatologie·2016
Same author

[Pathogenic cells of rheumatic inflammation as the target of modern therapies].

Zeitschrift fur Rheumatologie·2015

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Context:

  • Interferon alpha (IFN-α) is an established therapy for hairy cell leukemia, chronic myelogenous leukemia, and benign larynx papilloma.
  • The therapeutic application of cytokines for most malignant diseases is still in its early stages.
  • Cytokine-based therapies represent a developing frontier in cancer treatment.

Purpose:

  • To review the current therapeutic applications of interferon alpha and explore emerging cytokine-based strategies for cancer treatment.
  • To highlight novel approaches combining cytokines with other therapies for improved efficacy.
  • To assess the potential of new therapeutic modalities for challenging malignancies.

Summary:

  • Interferon alpha (IFN-α) has demonstrated therapeutic value in specific hematological malignancies and benign conditions.
  • Emerging strategies involve combining cytokines with cytotoxic agents, activated immune cells (T-lymphocytes and NK cells), and cytokine cocktails.
  • Clinical studies suggest cautious optimism for new cytokine-based treatments in Hodgkin's disease, non-Hodgkin's lymphomas, and solid tumors.

Impact:

  • Advances in cytokine therapy could lead to more effective treatments for various cancers.
  • Combination therapies may enhance immune responses and overcome treatment resistance.
  • Further research and clinical trials are crucial for realizing the full potential of cytokines in oncology.

Related Experiment Videos